Hamilton Herald Masthead


Front Page - Friday, February 19, 2021

Erlanger launches new GI trial to increase early colon cancer detection

Erlanger Health System has launched a clinical trial looking at the use of artificial intelligence technology for improving polyp detection during colonoscopies conducted with Magentiq Eye’s ME-APDSTM device.

The trial utilizes artificial intelligence software during routine colonoscopies to identify abnormalities called polyps in the lining of the colon.

The researchers aim to increase polyp detection rates in patients, with the AI acting as an extra set of eyes for the endoscopist. The device’s software reads the video screen at the same time as the doctor performing the colonoscopy.

“With this system, we aim to have more accurate colonoscopy tests and more polyps detected,” says Dr. Dror Zur, CEO of Magentiq Eye.

The AI software was taught how to detect abnormalities after being fed thousands of images showing these issues in various stages and forms.

“We think cancers that happen between colonoscopies are due to missed polyps hiding behind the folds and difficult to find polyps,” says Dr. Arslan Kahloon, chief of gastroenterology at Erlanger Health System and principal physician for the Erlanger research team in the trial.

“If we can find these polyps with any kind of extra detection system, then we can deal with them accordingly.”

There is no additional risk or cost to patients compared to a regular colonoscopy, Erlanger says in a news release.

The study is open and recruiting participants. For more information or to make an appointment, call 423 778-4830.

The study is in collaboration with the University of Tennessee Medical School and CTN2 Clinical Trials of Tennessee.

Source: Erlanger